Search Blog
Categories
November 2013
M T W T F S S
« Oct   Dec »
 123
45678910
11121314151617
18192021222324
252627282930  

Tags

OXBT, HZNP, PPHM and NWBO added to NASDAQ Healthcare Stock Watch List at GSR

admin

By Growing Stock Report

New York, NY – (ACCESSWIRE) – 11/11/2013 – Growing Stock Report initiates its NASDAQ Healthcare Active Stock Watch List adding Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), Horizon Pharma, Inc. (NASDAQ:HZNP), Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), and Northwest Biotherapeutics, Inc. (NASDAQ:NWBO).

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a development stage company that engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States is currently up (+3.62%) on 1,949,629 shares traded after Oxygen Biotherapeutics Received $6 Million in Net Proceeds from Warrant Exercises. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) is currently up (+4288.89%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Healthcare Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=OXBT&SubId=AW

Horizon Pharma, Inc. (NASDAQ:HZNP) a specialty pharmaceutical company that through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases is currently down (-1.05%) on 766,167 shares traded after Horizon Pharma and Mundipharma Signed Exclusive Agreement to Commercialize LODOTRA in the Middle East and Africa. Horizon Pharma, Inc. (NASDAQ:HZNP) is currently down (-10.4%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NASDAQ Healthcare Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Horizon Pharma, Inc. (NASDAQ:HZNP)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=HZNP&SubId=AW

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) a biopharmaceutical company that engages in the development of monoclonal antibodies focused on the treatment and diagnosis of cancer is currently up (+3.46%) on 577,985 shares traded after Peregrine presented data on bavituximab combined with anti-CTLA-4 antibodies. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) is currently up (+98.55%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Healthcare Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=PPHM&SubId=AW

Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) a development stage biotechnology company that engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States is currently up (+16.26%) on 1,278,192 shares traded after NW Bio’s DCVax was Featured On Fox News And Fox Business News. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) is currently up (+40.94%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Healthcare Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Northwest Biotherapeutics, Inc. (NASDAQ:NWBO)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=NWBO&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.growingstockreport.com/

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com